

Is Gemmily 28 Day still hard to find in 2026? Get the latest on availability, pricing, alternatives, and how to find it in stock at a pharmacy near you.
If you've been trying to fill your Gemmily 28 Day prescription and keep hitting dead ends, you're not alone. Since late 2025, patients across the country have reported difficulty finding Gemmily at their usual pharmacies. Some have been told it's on backorder. Others have been told their pharmacy simply can't get it.
In this update, we'll cover the current state of Gemmily availability, explain why the shortage is happening, look at what it costs in 2026, and share practical steps you can take to get your birth control filled.
As of early 2026, Gemmily 28 Day is not listed on the official FDA or ASHP drug shortage databases. However, "not on the official list" doesn't mean it's easy to find. Drug shortages can exist in practice — affecting real patients — even when they haven't been formally reported to federal agencies.
Patient reports on forums and social media suggest that Gemmily has been intermittently unavailable at many chain pharmacies since November 2025. Some patients have reported calling 5 to 10 pharmacies before finding one with Gemmily in stock.
The situation appears to be improving gradually, but availability remains inconsistent depending on your location and pharmacy.
Several factors are contributing to Gemmily's limited availability:
Gemmily is made by Xiromed, LLC — and they are currently the only manufacturer of this specific soft gelatin capsule formulation. When a single company is the sole source for a medication, any production delay, raw material issue, or distribution hiccup can create widespread shortages.
While the active ingredients in Gemmily (Norethindrone Acetate 1 mg / Ethinyl Estradiol 20 mcg) are available from many manufacturers in tablet form, the soft gelatin capsule version is exclusive to Xiromed (Gemmily) and AbbVie (Taytulla). This limits the supply pool for patients who specifically need or prefer the capsule form.
As insurance plans push patients toward generics, demand for Gemmily has increased since it's the only generic alternative to brand-name Taytulla. Production may not have kept up with this shift.
Broader pharmaceutical supply chain issues — including raw material sourcing and distribution logistics — have affected many medications in recent years. Oral contraceptives have not been immune to these pressures.
Pricing for Gemmily varies widely depending on whether you have insurance and which pharmacy you use:
For a complete guide to saving money, see: How to Save Money on Gemmily 28 Day in 2026.
If you can't find Gemmily, you have several options:
The following pills contain the same active hormones at the same doses as Gemmily, just in different forms:
For a detailed comparison, read: Alternatives to Gemmily 28 Day.
Taytulla is the brand-name version of Gemmily with the same capsule formulation. It's more expensive (up to $300 without insurance), but Allergan/AbbVie offers a savings card that may bring the cost to as little as $25 per fill for commercially insured patients.
Here are practical steps to locate Gemmily:
The Gemmily 28 Day availability situation in 2026 is improving but not yet resolved. If you're having trouble finding it, don't panic — you have options. Use Medfinder to check pharmacy availability, talk to your prescriber about alternatives, and plan ahead with early refills.
Your birth control shouldn't be a source of stress. With the right tools and information, you can stay protected even when pharmacy shelves are running low.
Related reading:
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.